PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma
Previous studies showed that PPAR-gamma (PPARG) ligands might serve as potential therapeutic agents for nonsmall cell lung cancer (NSCLC). However, a few studies reported the specific relationship between PPARG and lung squamous cell carcinoma (LSCC). Here, we made an effort to explore the relations...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2020/2510951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566495052300288 |
|---|---|
| author | Shunbin Shi Guiping Yu Bin Huang Yedong Mi Yan Kang Julia Pia Simon |
| author_facet | Shunbin Shi Guiping Yu Bin Huang Yedong Mi Yan Kang Julia Pia Simon |
| author_sort | Shunbin Shi |
| collection | DOAJ |
| description | Previous studies showed that PPAR-gamma (PPARG) ligands might serve as potential therapeutic agents for nonsmall cell lung cancer (NSCLC). However, a few studies reported the specific relationship between PPARG and lung squamous cell carcinoma (LSCC). Here, we made an effort to explore the relationship between PPARG and LSCC. First, we used mega-analysis and partial mega-analysis to analyze the effects of PPARG on LSCC by using 12 independent LSCC expression datasets (285 healthy controls and 375 LSCC cases). Then, literature-based molecular pathways between PPARG and LSCC were established. After that, a gene set enrichment analysis (GSEA) was conducted to study the functionalities of PPARG and PPARG-driven triggers within the molecular pathways. Finally, another mega-analysis was constructed to test the expression changes of PPARG and its driven targets. The partial mega-analysis showed a significant downregulated expression of PPARG in LSCC (LFC=−1.08, p value=0.00073). Twelve diagnostic markers and four prognostic markers were identified within multiple PPARG-LSCC regulatory pathways. Our results suggested that the activation of PPARG expression may inhibit the development and progression of LSCC through the regulation of LSCC upstream regulators and downstream marker genes, which were involved in tumor cell proliferation and protein polyubiquitination/ubiquitination. |
| format | Article |
| id | doaj-art-9d0e1db1e9254e208edfc9da15c38f02 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-9d0e1db1e9254e208edfc9da15c38f022025-02-03T01:04:06ZengWileyPPAR Research1687-47571687-47652020-01-01202010.1155/2020/25109512510951PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell CarcinomaShunbin Shi0Guiping Yu1Bin Huang2Yedong Mi3Yan Kang4Julia Pia Simon5Department of Thoracic Surgery, Suzhou Ninth People’s Hospital, Suzhou, Jiangsu Province 215200, ChinaDepartment of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu Province 214400, ChinaDepartment of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu Province 214400, ChinaDepartment of Cardiothoracic Surgery, Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu Province 214400, ChinaDepartment of General Surgery, Children’s National Medical Center, Washington, DC 20010, USANeuroimaging and Informatics Institute, University of Southern California, California, Los Angeles 90007, USAPrevious studies showed that PPAR-gamma (PPARG) ligands might serve as potential therapeutic agents for nonsmall cell lung cancer (NSCLC). However, a few studies reported the specific relationship between PPARG and lung squamous cell carcinoma (LSCC). Here, we made an effort to explore the relationship between PPARG and LSCC. First, we used mega-analysis and partial mega-analysis to analyze the effects of PPARG on LSCC by using 12 independent LSCC expression datasets (285 healthy controls and 375 LSCC cases). Then, literature-based molecular pathways between PPARG and LSCC were established. After that, a gene set enrichment analysis (GSEA) was conducted to study the functionalities of PPARG and PPARG-driven triggers within the molecular pathways. Finally, another mega-analysis was constructed to test the expression changes of PPARG and its driven targets. The partial mega-analysis showed a significant downregulated expression of PPARG in LSCC (LFC=−1.08, p value=0.00073). Twelve diagnostic markers and four prognostic markers were identified within multiple PPARG-LSCC regulatory pathways. Our results suggested that the activation of PPARG expression may inhibit the development and progression of LSCC through the regulation of LSCC upstream regulators and downstream marker genes, which were involved in tumor cell proliferation and protein polyubiquitination/ubiquitination.http://dx.doi.org/10.1155/2020/2510951 |
| spellingShingle | Shunbin Shi Guiping Yu Bin Huang Yedong Mi Yan Kang Julia Pia Simon PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma PPAR Research |
| title | PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma |
| title_full | PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma |
| title_fullStr | PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma |
| title_full_unstemmed | PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma |
| title_short | PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma |
| title_sort | pparg could work as a valid therapeutic strategy for the treatment of lung squamous cell carcinoma |
| url | http://dx.doi.org/10.1155/2020/2510951 |
| work_keys_str_mv | AT shunbinshi ppargcouldworkasavalidtherapeuticstrategyforthetreatmentoflungsquamouscellcarcinoma AT guipingyu ppargcouldworkasavalidtherapeuticstrategyforthetreatmentoflungsquamouscellcarcinoma AT binhuang ppargcouldworkasavalidtherapeuticstrategyforthetreatmentoflungsquamouscellcarcinoma AT yedongmi ppargcouldworkasavalidtherapeuticstrategyforthetreatmentoflungsquamouscellcarcinoma AT yankang ppargcouldworkasavalidtherapeuticstrategyforthetreatmentoflungsquamouscellcarcinoma AT juliapiasimon ppargcouldworkasavalidtherapeuticstrategyforthetreatmentoflungsquamouscellcarcinoma |